Cannabis Rescheduling Explained By Shawn Hauser, Juliana Todeschi, Charles Alovisetti, Cassia Furman Dec 18, 2025 The Controlled Substances Act of 1970 (the “CSA”) divides drugs into five schedules based on potential for abuse and medical value. Marijuana moving from...
President Trump directs cannabis be moved Schedule III, calling it “common sense”; major tax relief and a potential new Medicare pathway for hemp. {1DB17A23-3715-4D91-BDB6-1645E4407923} December 18, 2025 Today’s development President Trump has issued an Executive...
Table of Contents What happens next: DOJ and DEA pathways Once rescheduling occurs, then what? A potential bright spot: marijuana exports and the global market Will this effect the recently closed hemp loophole? Timing and what to expect going forward How Democrats...
By Shawn Hauser, Daniel Molina, Andrew Livingston, Will Woodlee, Helen Ryan Dec 16, 2025 In this collaborative analysis, Vicente LLP and the preeminent FDA law firm Kleinfeld, Kaplan & Becker LLP examine how the potential reclassification of cannabis into Schedule...
On Monday, the U.S. Supreme Court denied certiorari in Canna Provisions, Inc. et al. v. Bondi, a high-profile lawsuit that challenged the constitutionality of the federal prohibition of intrastate (and not interstate) cannabis activity. The denial offered no...
Precision Breeding in England: Navigating the New Regulatory Framework 9 December 2025 Authored and Edited by Hannah Whitmore, Ph.D.; K. Victoria Barker, Ph.D.; Victoria A. Randall, Ph.D. On 13 November 2025, England introduced the Genetic Technology (Precision...